OncoMatch/Clinical Trials/NCT07888140
Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
Official title: A Prospective, Multicenter, Randomized Controlled Trial Comparing Modular Robot-Assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy for Esophageal Cancer
Is NCT07888140 recruiting? Yes, currently enrolling (Oct 2026). This Phase 3 trial studies non-drug interventions for esophageal cancer.
This study evaluates the safety, efficacy, and health economic outcomes of modular robotic-assisted minimally invasive esophagectomy (RAMIE) compared with conventional thoracoscopic minimally invasive esophagectomy (MIE) in patients with resectable esophageal cancer. Participants are randomly assigned in a 1:1 ratio to undergo either modular robotic-assisted esophagectomy using the Carina™ Surgical Platform (experimental group) or conventional thoracoscopic esophagectomy (control group). The primary endpoint is the rate of Textbook Outcome (TO) within 30 days post-operation. Secondary endpoints include operative parameters, quality of life, overall survival, disease-free survival, and health economic metrics.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07888140 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages